Author response for 'Maintenance of Glycemic Control with Liraglutide versus Oral Antidiabetic Drugs as Add‐on Therapies in Patients with Type 2 Diabetes Uncontrolled with Metformin Alone: A Randomized Clinical Trial in Primary Care ( LIRA‐PRIME )'

Autor: null Jeff Unger, null Dale C. Allison, null Margit Kaltoft, null Kavitha Lakkole, null Jayant K. Panda, null Chethana Ramesh, null Mehmet Sargin, null Elena Smolyarchuk, null Melissa Twine, null Benjamin Wolthers, null Gizem Yarimbas, null Marouan Zoghbi, null Dennis O'Keefe, null Murdo Ferguson, null Anil Gupta, null Ronald Akhras, null Sean Peterson, null Guy Chouinard, null Sameh Fikry, null Richard Tytus, null David Crowley, null Pierre Filteau, null Sandra Barrera Silva, null Alexander Gonzalez, null Luis Gomez‐Botero, null Ghanshyam Pangtey, null S. Prabhu, null Pooja Khosla, null Arun Narayan, null Anil Awasthi, null Rohan Sequeria, null Reema Kashiva, null K. N. Manohar, null Ashwini Joshi, null Ajay Agarwal, null S. S. Ramesh, null Sanjay Agarwal, null Dipti Chand, null Dinesh Jain, null Ram Kaulgud, null Arija Lace, null Georges Bou Haidar, null Marwan Zoghbi, null Rania Sakr, null Grace Abi Rizk, null Tatiana Stepanova, null Albina Golovach, null Ruslan Sardinov, null Sergey Martsevich, null Branka Djuric‐Pejovic, null Svetlana Manojlovic‐Kulovic, null Jelena Bajic, null Danica Bacanin‐Jovanovic, null Snezana Stojilkovic, null Ivan Kostic, null Burcu Dogan, null Mehmet Burak Aktuglu, null Ozlem Cigerli, null Marshall Anderson, null William Byars, null David Butuk, null Kenneth Cohen, null Alexander Dela Llana, null Ankur Doshi, null Bryan Feldman, null Neil Fraser, null Michael Lillestol, null Robert Hippert, null Sashi Makam, null Stuart Stoller, null Lawrence Allen, null Richard Beasley, null Ramin Farsad, null Horacio Hidalgo, null Michael Soboeiro, null Kenneth Blaze, null William Simon, null Eric Dedeke, null Brian Everhart, null Michelle Look, null James Kahrs, null Melissa Poindexter, null Stephen Falkowski, null Clancy Cone, null Charles Crump, null Richard Jackson, null Augusto Focil, null Terence Hart, null Brent Hella, null Susan Kemp, null Cesar Albarracin, null Martin Schear, null Dwayne Williams, null Dwayne O. Williams, null John Willis, null Thomas Wolf, null Jennifer Bellucci‐Jackson, null Jonathan Condit, null Munib Daudjee, null Robert Detweiler, null Michael DiGiovanna, null Neil Farris, null Matthew Finneran, null Frank Fusco, null Peter Gagianas, null Sidney Gorton, null Marvin Heuer, null Jose Alvarez, null Gary Korff, null Joseph Lomboy, null Richard Lorraine, null Charles Lovell, null Caroline Mbogua, null Deirdre McMullen, null Richard Murphy, null Henry Naddaf, null Thomas O'Connor, null Stephen Ong, null Bryce Palchick, null David Pham, null Marina Raikhel, null Mercedes Samson, null Horia Tatu, null Henry Traylor, null Jeffrey Unger, null Dave Webster, null Kathleen Harris, null Steven Bauer, null Gary Bedel, null Mark Benson, null Isaac Beshay, null Rafael Canadas, null Cathy Hurley, null Thomas Davis, null H. Jackson Downey, null Gregory Haase, null Lee Herman, null Moises Issa, null Randal Jacks, null Curtis Jantzi, null David Johnson, null Ted Kubicki, null Reginald Parker, null Raman Purighalla, null Thaddeus Riley, null Gildardo Ceballos, null Robert Schreiman, null Robert Scott, null Matthew Lewis, null Amit Shah, null Charles Sharpe, null Kanagaratnam Sivalingam, null Stephen Smith, null Joseph Woolley, null Dilawar Ajani, null Eric Ball, null Daniel Schlosser, null Elmer Stout, null Moshir Jacob, null Bradley Block, null Wilfred McKenzie, null Carl Meisner, null Timothy Kitchen, null Daniel Koontz, null Joseph Labuda, null Howard Wenocur, null Robert Broker, null Zeeshan Shaikh, null Marcy Goisse, null David Headley, null David M. Headley, null Elba Perez‐Vargas, null Christopher Chow, null Alex Guevara, null Ralph Wade, null John Sibille, null Ajit Shah, null Kenneth Fox, null Vonda Houchin, null John Sensenbrenner, null Boyde Harrison, null Otis Barnum, null Bruce Weber, null Joseph Risser, null Steven Barag, null Anita Mercado, null Royce Solano, null Steve Simpson, null Kari Uusinarkaus, null Jose Burbano, null Richard Glover, null Ciro Reyes, null Julian Gonzalez, null C. Sofley, null Timothy Dao, null Michael Winnie, null Howard Ellison, null Tarek Hassanein, null Govinda Lohani, null Jon McRae, null Fadi Saba, null James Shoemaker, null Kelly Taylor, null Miguel Trevino, null Hernan Salazar, null Irene Sobolevsky, null Daniel Pomposini, null Garth Vaz, null Mark Fredrick, null Larry Berman, null Gregory Allen, null Maja Delibasic, null Carl Griffin, null Bram Wieskopf, null Aron Schlau, null Wayne Reynolds, null S. Michael Sutton, null Allen Geltzer, null Matthew Hummel, null Thomas Fiel, null Scott Kaiser, null David Francyk, null Kevin Pounds, null William Kirby, null Peter Levins, null Gregston Nelson, null LIRA‐PRIME investigators

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f602a48eaac0c8cbd0ed687d5cefbec
https://doi.org/10.1111/dom.14566/v3/response1

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Autor: Julie Derving Karsbøl, Shin-ichi Harashima, Stephen C. Bain, Thomas Kruse Hansen, George Tsoukas, Jeffrey Unger, Christopher Sorli

Publikováno v: The Lancet Diabetes & Endocrinology. 5:251-260

Summary Background Despite a broad range of pharmacological options for the treatment of type 2 diabetes, optimum glycaemic control remains challenging for many patients and new therapies are necessary. Semaglutide is a glucagon-like peptide-1 (GLP-1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e8d41eb20ff6e0e1a1cd21f0059e1c5
https://doi.org/10.1016/s2213-8587(17)30013-x

Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980

Autor: Hailing Guo, Diego Bellido, Vanita R. Aroda, Elisabeth Niemoeller, Elisabeth Souhami, Jeffrey Unger, Akane Takami, Richard M. Bergenstal, Carol Wysham, Julio Rosenstock, Guillermo González-Gálvez

Publikováno v: Diabetes Care

This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadeq

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb30e599940886b504bf8cccad47d704
https://pubmed.ncbi.nlm.nih.gov/27650977

Insulin initiation and intensification in patients with T2DM for the primary care physician

Autor: Jeffrey Unger

Publikováno v: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Type 2 diabetes mellitus (T2DM) is characterized by both insulin resistance and inadequate insulin secretion. All patients with the disease require treatment to achieve and maintain the target glycosylated hemoglobin (A1C) level of 6.5%–7%. Pharmac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad247de4e448c00a859edf681a73b634
http://europepmc.org/articles/PMC3139533

Composition of the audit committee: Ensuring members meet the new independence and financial literacy rules

Autor: Jeffrey Unger, Gregory N Racz, Adam O Emmerich

Publikováno v: International Journal of Disclosure and Governance. 2:67-80

Responding to the corporate scandals that have recently dominated the front pages of US newspapers, the Sarbanes–Oxley Act, the Securities and Exchange Commission (SEC) and the major US securities markets have imposed a number of sweeping corporate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::df2b4bb00d7ff2e6d41d951498236cbd
https://doi.org/10.1057/palgrave.jdg.2040043